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Abstract 
Objective: It is unclear whether serum uric acid (SUA) is associated with 
development of new-onset diabetes (NOD) in patients with hypertension and left ventricular 
hypertrophy (LVH). The aim of the present investigation was to test the hypothesis that SUA 
predicts development of NOD in these patients. 
Design and method: In the LIFE study, a double masked, parallel-group design, 9193 
patients with hypertension and electrocardiographic (ECG) LVH were randomized to 
losartan- or atenolol-based antihypertensive treatment and followed for a mean of 4.9 years. 
At baseline, 7489 patients with available SUA measurements did not have diabetes mellitus 
and were thus at risk of its development during the study. We used Cox regression analyses to 
investigate whether SUA predicted development of NOD. 
Results: NOD developed in 522 of 7489 patients. The association between baseline 
SUA and development of NOD was significant (HR 1.29 per SD [1.3 mg/dl], 95% CI 1.18-
1.42, P < 0.001) after adjustment for treatment with losartan vs. atenolol, baseline serum 
glucose, urinary albumin/creatinine ratio, estimated glomerular filtration rate and Framingham 
risk score, time-varying systolic and diastolic blood pressure, and time-varying LVH by 
Cornell voltage-duration product and Sokolow-Lyon voltage. In parallel analyses, baseline 
quartiles of SUA were significantly associated with increasing NOD (HR 1.28, 95% CI 1.18-
1.40, P < 0.001). Time-varying SUA was also associated with NOD (HR 1.10 per SD [1.3 
mg/dl], 95% CI 1.02-1.19, P = 0.015). 
Conclusion: Our analysis suggests that serum uric acid is an independent risk marker 
for new-onset diabetes in hypertensive patients with left ventricular hypertrophy. 
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The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study demonstrated 
the superiority of a losartan-based regimen over atenolol-based regimen for reduction of 
cardiovascular (CV) morbidity and mortality. The primary endpoint was a composite of 
cardiovascular death, myocardial infarction, and stroke. New-onset diabetes (NOD) was a 
pre-specified secondary endpoint.
1 
In LIFE patients NOD could be predicted by a risk score using significant variables 
from multivariate analyses, including serum glucose concentration, body mass index (BMI), 
serum HDL cholesterol concentration, systolic blood pressure (SBP) and prior use of 
antihypertensive drugs. Univariate analyses also showed a relation between serum uric acid 
(SUA) and risk of new-onset diabetes.
2
 In the same population baseline SUA was 
significantly associated with increased rate of the composite outcome of CV death, nonfatal 
myocardial infarction, or nonfatal stroke, especially in women,
3,4
 and with new-onset atrial 
fibrillation.
5
 SUA increased most in the group receiving atenolol. Losartan competes with the 
reabsorption of uric acid in the tubules and thereby leads to increased uric acid excretion by 
the kidneys, which may explain this difference.
3 
The association of hyperuricemia with hyperglycemia was first described by Kylin.
6
 In 
recent years the association of SUA with diabetes has been studied in different ethnic groups. 
According to these studies, it is not settled to what extent SUA independently predicts the 
development of diabetes.
7
 Whereas it was suggested that SUA is an independent risk factor 
for diabetes in the Rotterdam study, a cohort study of 4536 healthy subjects free from diabetes 
at baseline, aged 55 years and older,
8-10
 it has previously not been investigated whether SUA 
is associated with the development of NOD in patients with hypertension and left ventricular 
hypertrophy (LVH), a population with particular high risk of developing diabetes
2
 and in 
which SUA predicts major cardiovascular disease.
3
 Thus, the aim of the present investigation 
4 
was to test our hypothesis
2
 that SUA predicts development of NOD in hypertensive patients 
with LVH.
 
 
Methods 
Participants: The LIFE study population consists of 9193 patients aged 55 to 80 with 
previously untreated or treated essential hypertension and ECG-LVH, by Cornell voltage-
duration product or Sokolow-Lyon voltage.
11
 The LIFE study included patients with mean 
trough sitting diastolic BP of 95-115 mmHg and/or a mean sitting systolic BP of 160-200 
mmHg after 1-2 weeks on single-blind placebo treatment, who had not suffered a myocardial 
infarction or stroke within 6 months, and did not have known LV ejection fraction < 40%, or 
required treatment with a β-blocker, angiotensin converting enzyme-(ACE)-inhibitor, or 
angiotensin receptor-(AT1)-antagonist. The mean age at inclusion was 66.9 years, 54.1% were 
women, and the mean baseline BP was 174.4/97.8 mmHg.
1
  
Of the 9193 patients participating in the LIFE study, 1195 patients with diabetes 
mellitus at study baseline were excluded from the current analysis, leaving 7998 patients who 
were at risk of developing diabetes to be included in the present study. However, 509 patients 
did not have their SUA measured at baseline. These patients were excluded, leaving 7489 to 
be included in the statistical analyses. They were quite similar to the rather few patients who 
did not have SUA at baseline except for small differences in baseline DBP (98.0 vs. 98.9 
mmHg, P = 0.02) and ISH status (13.8 vs. 10.2 %, P = 0.02). 
If a patient who did not have diabetes at baseline had a non-fasting serum glucose 
concentration of 144 mg/dl or more, further investigations were made (including repeated 
fasting glucose or an oral glucose tolerance test, or both).
2
 New-onset diabetes mellitus was 
defined in the LIFE study according to the 1985 World Health Organization (WHO) criteria.
2
 
Once diabetes was determined to be present on the basis of this definition, the investigator 
5 
entered the information into the database. New recommendations for diagnosing NIDDM, 
mainly using fasting glucose of 126 mg/dl or more, were published by WHO in 1999 while 
the study was still in progress.
2
 Study protocol was not changed, and 1999 criteria was not 
advocated, but it was decided before the end of the study that all patients who were diagnosed 
with diabetes during the study would be included in the analyses regardless of the criteria 
(WHO 1985 or WHO 1999) upon which the diagnosis was based. The patients were followed 
for a mean of 4.9±0.8 years. 
Procedures: The LIFE study was a double-masked, randomized, parallel-group trial. 
The primary objective was to evaluate the long-term effects of losartan- compared with 
atenolol-based antihypertensive therapy in patients with hypertension and ECG-LVH on the 
incidence of cardiovascular morbidity and mortality.
1
 The LIFE study design, organization, 
clinical measures, endpoint definitions, basis for choice of comparative agents, statistical 
power calculations, recruitment details, baseline characteristics, 1-year follow-up, and 
primary results have been published.
1,12-13
 
The primary endpoint was a composite of cardiovascular death, non-fatal stroke, or 
non-fatal myocardial infarction. Other pre-specified outcome measures were components of 
the primary composite endpoint, total mortality, hospitalization for angina pectoris, 
hospitalization for heart failure, coronary or peripheral revascularization procedures, 
resuscitated cardiac arrest, and new-onset diabetes mellitus.
1
 
The trial protocol was approved by local ethics committees and performed in 
accordance with the Declaration of Helsinki. All participants gave their informed consent. 
The study was overseen by an independent data and safety monitoring board.  
Routine laboratory tests were performed in 2 central laboratories, with validation of 
comparable results using split samples. The study ran its full course and endpoint follow-up 
was stopped on September 16, 2001.
1
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Statistical methods: All endpoints were analyzed using the intention-to-treat 
approach. Participants who experienced > 1 endpoint were counted as having an event in all 
relevant endpoint analyses; however, only the first event in a specific category was counted in 
individual analyses.
2
  
Baseline clinical, demographic and laboratory data were assessed for association with 
new-onset diabetes. Estimated Glomerular Filtration Rate (eGFR) was calculated using the 
MDRD formula (175 x [(s-creat/88.4)
-1.154
] x age 
-0.203 
x gender constant (men: 1.00; women: 
0.742) and included as covariate in all multivariate models.  
Univariate Cox proportional hazard regression models were used to examine the 
association between SUA and other possible risk factors and the risk of new-onset diabetes, 
presented as relative risk (i.e. the hazard ratio [HR]) and its 95 % confidence interval (CI). 
Variables that had a significant univariate effect or were considered as clinically relevant were 
maintained when multivariate models were developed. Impact of SUA was calculated in a 
main multivariate model adjusting for study treatment with losartan vs. atenolol, baseline 
serum glucose, urinary albumin/creatinine ratio, eGFR and Framingham risk score, time-
varying systolic and diastolic blood pressure, and time-varying LVH by Cornell voltage-
duration product and Sokolow-Lyon voltage. We developed additional multivariate models, 
using the main multivariate model mentioned above and also adjusting for concomitant 
treatment with hydrochlorothiazide, baseline BMI and baseline HDL. When plausible, 
interaction analyses were performed using Cox proportional hazard models with SUA entered 
as time-varying covariate, a possible effect modifier entered as standard covariate and a 
multiplicative interaction product of time-varying SUA and the possible effect modifier 
entered as standard covariate. All the included time-varying variables were corrected for 
missing values: If a value was missing during follow-up, it was replaced by the previous 
value. These models were used to analyze baseline SUA, baseline quartiles of SUA, and time-
7 
varying SUA as predictors of NOD, computed per 1 SD (1.3 mg/dl) of mean baseline SUA 
for the continuous variables. The same models were also used to compare the highest quartile 
of SUA with the three lowest quartiles at baseline, and after 1, 2, 3 and 4 years in regards to 
risk of developing NOD. A two tailed P < 0.05 was required for statistical significance. 
 
Results 
Mean baseline SUA was 5.54±1.3 mg/dl, with a range of 1.16-11.93 mg/dl in the 7489 
patients included in the analysis. SUA values were normally distributed at baseline and after 
1, 2, 3 and 4 years. Average increase of SUA from baseline to study end was 0.74±1.3 mg/dl, 
also normally distributed. 
Demographic and clinical characteristics of the patients in relationship to baseline 
quartiles of SUA are compared in Table 1. There were significant differences between the 
quartiles of baseline SUA in age, gender, race, weight, height, BMI, diastolic blood pressure, 
pulse pressure, heart rate, hemoglobin, serum sodium, potassium, creatinine, eGFR, urinary 
albumin/creatinine ratio, total and HDL cholesterol, glucose, history of stroke, history of 
ischemic heart disease, alcohol and Framingham risk score. The groups were similar with 
respect to systolic blood pressure, Sokolow-Lyon voltage, Cornell voltage-duration product, 
smoking, physical exercise habits, TIA, peripheral vascular disease and chronic obstructive 
pulmonary disorder (COPD). 
 During a mean follow-up of 4.9±0.8 years, new-onset diabetes mellitus developed in 
522 patients (7%). There was a higher incidence of diabetes in higher quartiles of baseline 
SUA. The incidence of NOD rose from about 3% in the 1
st
 quartile of SUA at baseline to 
approximately 7% in the 2
nd
 and 3
rd
 quartiles of baseline SUA to nearly 11% in the 4
th
 quartile 
of baseline SUA (Figure 1). 
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 The statistically significant univariate predictors of NOD were baseline and time-
varying SUA, BMI, baseline Cornell product, creatinine, eGFR, Framingham risk score, 
glucose, exercise, HDL, heart rate, hemoglobin, potassium, pulse pressure, systolic blood 
pressure, total cholesterol, treatment (atenolol vs. losartan), weight, maximal dose of 
hydrochlorothiazide during study, time-varying Sokolow-Lyon and Cornell product, and time-
varying diastolic blood pressure (Supplemental Table). 
The relation of SUA to the development of new-onset diabetes is examined further in 
Table 2. In the main multivariate model, after adjustment for treatment with losartan vs. 
atenolol, baseline serum glucose, urinary albumin/creatinine ratio, eGFR and Framingham 
risk score, time-varying systolic and diastolic blood pressure, and time-varying LVH by 
Cornell voltage-duration product and Sokolow-Lyon voltage, HR was 1.29 per SD (1.3 mg/dl) 
increase in baseline SUA, 95% CI 1.18-1.42, P < 0.001. In parallel analyses, baseline 
quartiles of SUA were significantly associated with NOD (HR 1.28, 95% CI 1.18-1.40, P < 
0.001) and time-varying (change from baseline) SUA was also associated with NOD (HR 
1.10 per SD [1.3 mg/dl] increase, 95% CI 1.02-1.19, P = 0.015). 
 In additional models using the main multivariate model and also adjusting for 
concomitant treatment with hydrochlorothiazide and/or baseline BMI and/or baseline HDL, 
the association of baseline SUA and baseline quartiles of SUA with NOD was still highly 
significant (Table 2). When using the main multivariate model and also adjusting for 
concomitant treatment with hydrochlorothiazide, the association between time-varying SUA 
and NOD was no longer significant (HR 1.07, 95% CI 1.00-1.16, P = 0.066). Similarly, when 
using the main multivariate model and also adjusting for baseline HDL and BMI, the 
association between time-varying SUA and NOD was not significant (HR 1.03, 95% CI 0.95-
1.11, P = 0.50). As a consequence hereof we analyzed potential interactions with time-varying 
SUA and NOD; study treatment (HR 0.91, 95% CI 0.79-1.04, P = 0.18), maximal dose of 
9 
hydrochlorothiazide (HR 0.99, 95% CI 0.99-1.00, P = 0.04), HDL (HR 1.39, 95% CI 1.14-
1.70, P = 0.001) and BMI (HR 1.00, 95% CI 0.99-1.01, P = 0.40). 
Our analyses showed an increasing risk of developing NOD with higher baseline 
quartile of SUA. The results compared to quartile 1, were HR 2.30, 95% CI 1.69-3.13, P < 
0.001 for quartile 2, HR 2.38, 95% CI 1.75-3.25, P < 0.001 for quartile 3, and HR 3.65, 95% 
CI 2.73-4.89 for quartile 4. These results were unaltered when adjusting for treatment.  
In univariate Cox analyses, the risk of NOD in the highest quartile of SUA compared 
to the lowest three quartiles was HR 1.94, 95% CI 1.62-2.31, P < 0.001 at baseline, HR 2.26, 
95% CI 1.87-2.73, P < 0.001 at year 1, HR 1.73, 95% CI 1.37-2.19, P < 0.001 at year 2, HR 
2.02, 95% CI 1.52-2.69, P < 0.001 at year 3, and HR 1.87, 95% CI 1.27-2.75, P = 0.001 at 
year 4 (Figure 2). 
In the main multivariate model adjusting for study treatment with losartan vs. atenolol, 
baseline serum glucose, urinary albumin/creatinine ratio, eGFR and Framingham risk score, 
time-varying systolic and diastolic blood pressure, and time-varying LVH by Cornell voltage-
duration product and Sokolow-Lyon voltage, the risk of NOD in the highest quartile of SUA 
compared to the lowest three quartiles was HR 1.48, 95% CI 1.22-1.80, P < 0.001 at baseline, 
HR 1.91, 95% CI 1.55-2.34, P < 0.001 at year 1, HR 1.44, 95% CI 1.12-1.86, P = 0.004 at 
year 2, HR 1.70, 95% CI 1.25-2.31, P = 0.001 at year 3, and HR 1.53, 95% CI 1.02-2.31, P = 
0.04 at year 4. 
 After adjusting for study treatment, concomitant treatment with hydrochlorothiazide, 
baseline BMI, HDL, serum glucose, eGFR, urinary albumin/creatinine ratio and Framingham 
risk score, time-varying systolic and diastolic blood pressure, and time-varying LVH by 
Cornell voltage-duration product and Sokolow-Lyon voltage, the risk of NOD in the highest 
quartile of SUA compared to the lowest three quartiles was HR 1.27, 95% CI 1.05-1.55, P = 
0.015 at baseline, HR 1.55, 95% CI 1.25-1.91, P < 0.001 at year 1, HR 1.16, 95% CI 0.89-
10 
1.50, P = 0.27 at year 2, HR 1.37, 95% CI 1.00-1.86, P = 0.05 at year 3, and HR 1.28, 95% CI 
0.85-1.93, P = 0.24 at year 4. 
 
Discussion 
The present investigation demonstrates that SUA is associated with NOD in hypertensive 
patients with LVH, independent of other predictors of diabetes in the LIFE study. The 
associations were strong, both with regards to SUA levels at baseline, time-varying SUA, and 
SUA quartiles at baseline and quartiles at 1, 2, 3 and 4 years after baseline. Our findings in 
hypertensive patients with LVH are in agreement with findings in other populations.
6-10 
 
Relationship of diabetes to SUA levels 
In our analyses we considered baseline SUA, baseline quartiles of SUA and time-varying 
SUA as predictors of NOD. We also compared the lowest quartile of baseline SUA with each 
of the others. Finally the highest quartile of SUA was compared to the three lowest quartiles 
at baseline and after 1, 2, 3 and 4 years, with respect to risk of NOD. In all these analyses, the 
results were clearly significant. Furthermore, a strength of our findings is that adjusting the 
analysis for study treatment with losartan vs. atenolol, baseline serum glucose, urinary 
albumin/creatinine ratio, eGFR and Framingham risk score, time-varying systolic and 
diastolic blood pressure, and time-varying LVH by Cornell voltage-duration product and 
Sokolow-Lyon voltage did not influence the statistical significance of the association of SUA 
with NOD.  
Using an additional model adjusting for study treatment and hydrochlorothiazide, 
baseline BMI, HDL, serum glucose, eGFR, urinary albumin/creatinine ratio and Framingham 
risk score, time-varying systolic and diastolic blood pressure, and time-varying LVH by 
Cornell voltage-duration product and Sokolow-Lyon voltage, the associations were generally 
11 
weaker but still significant, except for the analyses of time-varying SUA as a predictor of 
NOD, and comparing the highest quartile of SUA with the rest of the population 2, 3 and 4 
years after baseline in regards to risk of NOD. The additional model included BMI and HDL, 
which are well known risk factors of new-onset diabetes, usually emphasized more strongly 
than SUA.
2
 Our results suggest that even if there is a strong association between SUA and 
NOD, BMI and HDL and also baseline glucose (which was adjusted for in all models) are 
more important predictors, and become still more important over time. 
The ability of time-varying SUA in predicting diabetes was weaker than baseline SUA 
and influenced particularly by concomitant treatment with hydrochlorothiazide and by HDL 
cholesterol. This finding with hydrochlorothiazide may represent the well known strong 
association of diuretic use with new onset diabetes. The much stronger ability of HDL 
cholesterol to interact with the time-varying SUA and new diabetes relationship may however 
suggest an interesting biological pathway and give insight into the mechanism of how SUA 
manifests its impacts on new diabetes. Interaction with randomized treatment was however 
not significant arguing against benefits of losartan on preventing new diabetes (2) was 
through the SUA effects (3). 
The reference range of SUA is between 2.0 and 7.0 mg/dl for men, and between 2.0 
and 6.0 mg/dl for women.
14 
The total population of this study had a mean value of 5.5 mg/dl 
at baseline, which is high normal. At year 4 the mean value was 6.1 mg/dl. The patients in the 
upper quartile of baseline SUA are hyperuremic on average, with mean value of 7.3 mg/dl, 
ranging from 6.4 to 11.9 mg/dl.  
The analyses show an increasing association from baseline to year 1, and from year 2 
to year 3. The association decreased from year 1 to year 2 and from year 3 to year 4 (Figure 
2). This is most likely due to random variation. As the power analyses of the LIFE study was 
based on the composite cardiovascular endpoint, and not on the endpoint of NOD, such 
12 
variations may appear due to limited statistical power when analyzed from one year to the 
next. 
High SUA as a risk factor for diabetes has been a matter of discussion. Hyperuricemia 
has been considered to be a result of insulin resistance rather than its precursor.
9 
A number of 
studies have reported significant associations between SUA levels and individual components 
of the metabolic syndrome, which increase the risk of atherosclerotic cardiovascular disease 
and type 2 diabetes. A study by Hyon et al indicated that the prevalence of the metabolic 
syndrome increased substantially with increasing levels of serum uric acid.
15 
A study in rats 
showed that fructose-induced hyperuricemia plays a pathogenic role in the metabolic 
syndrome, and it has been shown that SUA is associated with oxidative stress and production 
of tumor necrosis factor-α, which are both related to the development of diabetes.9  
Moreover, it has been shown that uric acid increases insulin resistance in animal 
models by inhibiting the bioavailability of nitric oxide, which is essential for insulin-
stimulated glucose uptake.
16
 Uric acid may also contribute to the risk of diabetes mellitus by a 
direct cytotoxic effect on the pancreatic B-cells via its alloxan-like derivatives.
17
 In our study 
we observed that uric acid could be related to the development of diabetes, and the above 
mentioned findings support high SUA as a possible risk factor of type 2 diabetes. 
 
Limitations 
The LIFE study population was of older age and mainly white ethnicity. Participants were 
derived from a high-risk population of hypertensive patients and the outcome should be 
interpreted in this context. The adoption of a 1999 WHO recommendation for diagnosing type 
2 diabetes during the later part of the LIFE study, led the Steering Committee to accept 
patients with diabetes diagnosed according to either the 1999 and 1985 recommendations.
2 
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Conclusion 
Serum uric acid is independently associated with new-onset diabetes in hypertensive patients 
with LVH. There are several factors which are significantly associated with development of 
new-onset diabetes in hypertensive patients with LVH.
2
 Some factors are well-known, like 
obesity, high serum glucose concentration and low HDL cholesterol values. These are 
probably more important predictors for NOD than SUA, and well-established targets for 
therapeutic intervention in order to prevent development of diabetes. However, our current 
findings have potentially important clinical implications. Further investigation with uric acid 
lowering drugs (e.g. allopurinol) may evaluate if serum uric acid may be an independent 
target for therapeutic intervention in hypertensive patients with ECG-LVH to prevent the 
development of new-onset diabetes mellitus. 
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Jersey. The data base is in the possession of the investigators (the authors of this paper) who 
have also done all statistical work. Authors Aud Høieggen, Sverre E. Kjeldsen, Michael Hecht 
Olsen, Hans Ibsen, Lars Lindholm, Björn Dahlöf, Richard B. Devereux, Peter M. Okin, and 
Kristian Wachtell have received lecture honoraria from Merck & co. and other pharmaceutical 
companies. 
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Figure legends: 
 
Figure 1. Incidence of New-Onset Diabetes (n = 522) According to Baseline Quartiles of 
Serum Uric Acid. P < 0.001 for trend (Chi-Square) 
 
Figure 2. The highest versus the three lowest quartiles of SUA and risk of new-onset diabetes 
at baseline and at years 1 - 4. P < 0.05 (Cox regression analyses) 
 
Footnotes to Figure 2 
*Non-Significant. 
Main Multivariate Model: Adjusted for treatment, baseline serum glucose, urinary 
albumin/creatinine ratio, eGFR and Framingham risk score, time-varying systolic and 
diastolic blood pressure, and time-varying LVH by Cornell voltage-duration product and 
Sokolow-Lyon voltage. 
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Table 1. Baseline Demographic and Clinical Characteristics of Patients without Diabetes at 
Baseline by Quartiles of Baseline SUA (n = 7489). 
 
Quartile 1 
n=1884 
Quartile 2 
n=1896 
Quartile 3 
n=1829 
Quartile 4 
n=1880 
P 
Value 
Range (mg/dl) 1.16-4.62 4.64-5.48 5.49-6.33  6.35-11.93  
 Serum uric acid (mg/dl) 4.0 ±0.6 5.1 ±0.2 5.9 ±0.2 7.3 ±0.8 < 0.001 
Age (years) 67.4 ±7.0 67.2 ±7.0 66.7 ±6.9 66.2 ±7.0 < 0.001 
Women 1506 (80%) 1173 (62%) 848 (46%) 525 (28%) < 0.001 
Black race 56 (3%) 70 (4%) 89 (5%) 162 (9%) < 0.001 
Weight (kg) 71.0 ±13.3 76.1 ±12.9 80.0 ±13.8 84.4 ±14.8 < 0.001 
Height (cm) 164.0 ±8.3 166.7 ±9.2 168.4 ±9.5 171.0 ±9.1 < 0.001 
BMI (kg/m
2
) 26.4 ±4.4 27.4 ±4.4 28.2 ±4.7 28.9 ±4.6 < 0.001 
Diastolic blood pressure (mmHg) 98 ±9 98 ±9 98 ±9 99 ±9 < 0.001 
Pulse pressure (mmHg) 77 ±15 77 ±15 75 ±15 75 ±16 < 0.001 
Alcohol (> 10 drinks/week) 38 (2.0%) 47 (2.5%) 78 (4.3%) 145 (7.7%) < 0.001 
Heart rate (beat/min) 74 ±11 73 ±11 73 ±11 73 ±11 0.02 
Systolic blood pressure (mmHg) 175 ±14 174 ±14) 173 ±14 174 ±14 0.08 
Sokolow-Lyon (mm) 30.0 ±9.8 30.0 ±10.4 30.2 ±10.6 30.6 ±10.7 0.20 
Never exercise 403 (21%) 365 (19%) 377 (21%) 412 (22%) 0.20 
Current smokers 310 (17 %) 317 (17%) 300 (16%) 331 (18%) 0.74 
Cornell product (mm x ms) 2830.1 ±1077.0 2824.7 ±1057.8 2796.8 ±1023.9 2811.2 ±1029.4 0.77 
Laboratory values 
    Hemoglobin (g/dl) 13.8 ±1.1 14.1 ±1.1 14.4 ±1.2 14.6 ±1.3 < 0.001 
Serum sodium (mEq/l) 140.1 ±2.7 140.3 ±2.4 140.5 ±2.5 140.7 ±2.4 < 0.001 
Serum potassium (mEq/l) 4.1 ±0.4 4.2 ±0.4 4.2 ±0.4 4.2 ±0.4 < 0.001 
Serum creatinine (mg/dl) 0.8 ±1.7 0.9 ±0.2 1.0 ±0.2 1.1 ±2.5 < 0.001 
Estimated GFR (ml/min) 72.5 ±14.2 69.7 ±13.8 68.5 ±14.6 65.0 ±15.5 < 0.001 
Urinary albumin/creat. ratio (mg/g) 31.6 ±106.2 46.5 ±340.2 51.2 ±174.0 80.4 ±280.1 < 0.001 
Serum total cholesterol (mg/dl) 239.8 ±42.5 235.9 ±42.5 235.9 ±42.5 232.0 ±42.5 < 0.001 
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Serum HDL cholesterol (mg/dl) 65.7 ±19.3 61.9 ±15.5 58.0 ±15.5 54.1 ±15.5 < 0.001 
Serum glucose (mg/dl) 95.5 ±18.0 97.3 ±18.0 99.1 ±18.0 102.7 ±19.8 < 0.001 
Medical history 
    Coronary heart disease 214 (11%) 267 (14%) 299 (16%) 326 (17%) < 0.001 
Congestive heart failure 12 (0.6%) 22 (1%) 33 (2%) 45 (2%) < 0.001 
Framingham risk score 16.8 ±7.2 19.9 ±8.4 22.6 ±9.0 25.4 ±9.1 < 0.001 
Stroke 63 (3%) 63 (3%) 68 (4%) 95 (5%) 0.02 
TIA 61 (3%) 61 (3%) 71 (4%) 88 (5%) 0.06 
Isolated systolic hypertension 282 (15%) 273 (14%) 251 (14%) 228 (12%) 0.07 
Peripheral vascular disease 102 (5%) 88 (5%) 102 (6%) 118 (6%) 0.18 
COPD 64 (3%) 73 (4%) 79 (4%) 86 (5%) 0.27 
Values are either mean ± SD or number (%) of subjects.  
BMI = body mass index. Sokolow-Lyon voltage = (SV1+ RV5-6) and Cornell voltage-duration 
product = (RAvL + SV3 + 6 mm for women) x QRS are criteria of LVH in electrocardiogram. GFR = 
glomerular filtration rate; estimated GFR is calculated by the MDRD formula (175 x [(s-creat/88.4)
-
1.154
] x age 
-0.203 
x gender constant (men: 1.00; women: 0.742). Framingham risk score = risk score 
based on gender, cholesterol, HDL cholesterol, smoking status, presence of diabetes and LVH, systolic 
blood pressure and BMI. TIA = transitory ischemic attack. COPD = chronic obstructive pulmonary 
disease. 
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Table 2. Cox Proportional Hazards Models Demonstrating the Association of Serum 
Uric Acid with New-onset Diabetes in Patients without Diabetes at Baseline (n = 7489). 
Variable 
 
Hazard Ratio (95% CI) P Value 
Baseline SUA, pr SD (1.3 mg/dl) 
 
 
Univariate 1.43 (1.32-1.55) < 0.001 
 
Treatment adjusted 1.43 (1.32-1.55) < 0.001 
 
Multivariate main model 1.29 (1.18-1.42) < 0.001 
 
Multivariate model
1
 1.30 (1.19-1.43) < 0.001 
 
Multivariate model
2
 1.24 (1.13-1.36) < 0.001 
 
Multivariate model
3
 1.20 (1.09-1.32) < 0.001 
 
Multivariate model
4
 1.16 (1.06-1.28) 0.002 
 
Multivariate model
5
 1.17 (1.07-1.29) 0.001 
Baseline Quartiles of SUA
6 
  
 
Univariate 1.43 (1.32-1.55)
 
< 0.001 
 
Treatment adjusted 1.43 (1.32-1.55)
 
< 0.001 
 
Multivariate main model 1.28 (1.18-1.40) < 0.001 
 
Multivariate model
1
 1.28 (1.17-1.40) < 0.001 
 
Multivariate model
2
 1.23 (1.13-1.35) < 0.001 
 
Multivariate model
3
 1.20 (1.10-1.31) < 0.001 
 
Multivariate model
4
 1.17 (1.07-1.28) 0.001 
 
Multivariate model
5
 1.17 (1.06-1.28) 0.001 
Time-varying SUA, pr SD (1.3 mg/dl) 
 
 
Univariate 1.22 (1.14-1.30) < 0.001 
 
Treatment adjusted 1.20 (1.12-1.28) < 0.001 
 
Multivariate main model 1.10 (1.02-1.19) 0.015 
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Multivariate model
1
 1.07 (1.00-1.16) 0.066 
 
Multivariate model
2
 1.08 (1.00-1.17) 0.056 
 
Multivariate model
3
 1.04 (0.96-1.12) 0.37 
 
Multivariate model
4
 1.03 (0.95-1.11) 0.50 
 
Multivariate model
5
 1.00 (0.92-1.08) 0.98 
Multivariate main model: Adjusted for treatment with losartan vs. atenolol, baseline 
serum glucose, urinary albumin/creatinine ratio, estimated GFR and Framingham risk 
score, time-varying systolic and diastolic blood pressure, and time-varying LVH by 
Cornell voltage-duration product and Sokolow-Lyon voltage. 
1
 Main model also adjusted for maximum dose hydrochlorothiazide during study. 
2
 Main model also adjusted for baseline HDL. 
3
 Main model also adjusted for baseline BMI. 
4
 Main model also adjusted for baseline BMI and HDL. 
5
 Main model also adjusted for baseline BMI, HDL and maximum dose 
hydrochlorothiazide during study. 
6
 HR indicates the trend across the 4 SUA quartiles. 
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Supplemental Table.  Univariate Predictors of New-onset Diabetes in Patients without 
Diabetes at Baseline (n = 7489). 
Variable Hazard Ratio (95% CI) P Value 
Serum uric acid (per SD [1.3 mg/dl]) 1.43 (1.32-1.55) < 0.001 
Time-varying SUA (per SD [1.3 mg/dl]) 1.22 (1.14-1.30) < 0.001 
Body Mass Index (per 1 kg/m
2
) 1.09 (1.08-1.10) < 0.001 
Baseline Cornell (per 1 mm x ms) 1.00 (1.00-1.00) < 0.001 
Creatinine (per 0.01 mg/dl) 1.01 (1.00-1.01) < 0.001 
Estimated GFR (per 1 ml/min) 0.99 (0.98-1.00) < 0.001 
Framingham risk score (per 1 % point) 1.03 (1.02-1.04) < 0.001 
Glucose (per 18 mg/dl) 1.72 (1.65-1.79) < 0.001 
HDL (per 38.7 mg/dl) 0.23 (0.18-0.29) < 0.001 
Heart rate (per 1 beat/min) 1.01 (1.01-1.02) < 0.001 
Hemoglobin (per 0.1  g/dl) 1.02 (1.01-1.03) < 0.001 
Pulse pressure (per 1 mmHg) 1.01 (1.01-1.02) < 0.001 
Systolic blood pressure (per 1 mmHg) 1.02 (1.01-1.02) < 0.001 
Total cholesterol (per 38.7 mg/dl) 0.86 (0.79-0.93) < 0.001 
Treatment (atenolol vs. losartan) 1.38 (1.16-1.64) < 0.001 
Weight (per 1 kg) 1.03 (1.03-1.04) < 0.001 
Hydrochlorothiazide, max dose during study 1.03 (1.02-1.04) < 0.001 
Time-varying Sokolow-Lyon (per 10.5 mm) 0.85 (0.78-0.94) 0.001 
Time-varying DBP (per 1 mmHg) 0.99 (0.98-1.00) 0.003 
Potassium (per 1 mEq/l) 0.72 (0.57-0.91) 0.006 
Exercise (yes vs. no) 0.77 (0.63-0.94) 0.01 
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Sokolow-Lyon (per 1 mm) 0.99 (0.98-1.00) 0.019 
Time-varying Cornell (per 1050 mm x ms) 1.09 (1.01-1.17) 0.02 
Diastolic blood pressure (per 1 mmHg) 1.01 (1.00-1.02) 0.10 
Height (per 1 cm) 1.01 (1.00-1.02) 0.21 
 
Some of the values in this table are converted from SI units to mg/dl. 
24 
 
 
  
Fig. 1
P<0.001 for trend 
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Fig. 2 
 
